ES2126606T3 - Terapia del sistema nervioso central mediante celulas modificadas geneticamente. - Google Patents

Terapia del sistema nervioso central mediante celulas modificadas geneticamente.

Info

Publication number
ES2126606T3
ES2126606T3 ES92925278T ES92925278T ES2126606T3 ES 2126606 T3 ES2126606 T3 ES 2126606T3 ES 92925278 T ES92925278 T ES 92925278T ES 92925278 T ES92925278 T ES 92925278T ES 2126606 T3 ES2126606 T3 ES 2126606T3
Authority
ES
Spain
Prior art keywords
nervous system
central nervous
therapy
genetically modified
modified cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92925278T
Other languages
English (en)
Inventor
Fred Gage
Theodore Friedmann
Michael B Rosenberg
Jon A Wolff
Malcolm Schinstine
Michael D Kawaja
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Application granted granted Critical
Publication of ES2126606T3 publication Critical patent/ES2126606T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
    • C12Y114/16002—Tyrosine 3-monooxygenase (1.14.16.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

SE EXPONEN METODOS PARA MODIFICACION GENETICA DE LAS CELULAS DEL DONANTE POR TRANSFERENCIA DE GENES CON INJERTO EN EL SISTEMA NERVIOSO CENTRAL PARA TRATAR CELULAS DEFECTUOSAS, ENFERMAS O DAÑADAS. LAS CELULAS MODIFICADAS DEL DONANTE PRODUCEN MOLECULAS FUNCIONALES QUE LLEVAN A CABO LA RECUPERACION O LA FUNCION MEJORADA DE LAS CELULAS DEL SNC. SE DESCRIBEN METODOS Y VECTORES PARA REALIZAR LA TRANSFERENCIA E INJERTO DEL GEN.
ES92925278T 1991-11-15 1992-11-13 Terapia del sistema nervioso central mediante celulas modificadas geneticamente. Expired - Lifetime ES2126606T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79289491A 1991-11-15 1991-11-15
CA002095300A CA2095300C (en) 1991-11-15 1993-04-30 Use of genetically modified cells to treat defects, disease or damage of the central nervous system
JP5136554A JPH06329559A (ja) 1991-11-15 1993-05-14 遺伝子的に修飾された細胞を移植して中枢神経系における欠陥、疾病、あるいは損傷を治療するための方法

Publications (1)

Publication Number Publication Date
ES2126606T3 true ES2126606T3 (es) 1999-04-01

Family

ID=27169416

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92925278T Expired - Lifetime ES2126606T3 (es) 1991-11-15 1992-11-13 Terapia del sistema nervioso central mediante celulas modificadas geneticamente.

Country Status (9)

Country Link
EP (1) EP0625195B1 (es)
JP (1) JPH06329559A (es)
AT (1) ATE175442T1 (es)
CA (1) CA2095300C (es)
DE (1) DE69228127T2 (es)
DK (1) DK0625195T3 (es)
ES (1) ES2126606T3 (es)
GR (1) GR3029362T3 (es)
WO (1) WO1993010234A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103226A (en) * 1994-08-12 2000-08-15 Arch Development Corporation Genetically engineered cells that produce produce L. Dopa
US6204053B1 (en) 1994-11-08 2001-03-20 Diacrin, Inc. Porcine cortical cells and their use in treatment of neurological deficits due to neurodegenerative diseases
US6294383B1 (en) 1994-11-08 2001-09-25 The Mclean Hospital Corporation Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases
WO1996022112A1 (en) 1995-01-17 1996-07-25 Genetic Therapy, Inc. Delivery of therapeutic agents by gene therapy
US5753505A (en) * 1995-07-06 1998-05-19 Emory University Neuronal progenitor cells and uses thereof
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
DE69914463T2 (de) 1998-03-13 2004-11-11 The University Of British Columbia, Vancouver Therapeutische chemokine rezeptor antagonisten
US6444205B2 (en) 1998-09-30 2002-09-03 Diacrin, Inc. Transplantation of neural cells for the treatment of chronic pain or spasticity
US20040120891A1 (en) 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
DK1159415T3 (da) * 1999-03-04 2010-05-03 Revivicor Inc Genetisk modifikation af somatiske celler og anvendelse deraf
WO2001075094A1 (en) * 2000-04-04 2001-10-11 Thomas Jefferson University Application of myeloid-origin cells to the nervous system
US7368425B2 (en) 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
US20050059584A1 (en) 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
US7378098B2 (en) 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US20030124095A1 (en) 2001-12-31 2003-07-03 Regents Of The University Of California Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex
KR101226702B1 (ko) * 2010-10-08 2013-01-25 충북대학교 산학협력단 인간 콜린 아세틸트랜스퍼라아제를 발현하는 인간 신경줄기세포 및 이의 용도
JP2021530507A (ja) 2018-07-18 2021-11-11 マンザニータ ファーマシューティカルズ，インク． 神経細胞に抗がん剤を送達するためのコンジュゲート、その使用方法及び製造方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3015383B2 (ja) * 1987-09-11 2000-03-06 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 形質導入した線維芽およびそれらの使用
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US6511823B1 (en) * 1990-08-20 2003-01-28 American Cyanamid Corporation Heparin binding neurotrophic factor gene sequence
WO1992009688A1 (en) * 1990-11-21 1992-06-11 Massachusetts Institute Of Technology MICE HAVING β2 MICROGLOBULIN GENE DISRUPTION

Also Published As

Publication number Publication date
JPH06329559A (ja) 1994-11-29
EP0625195B1 (en) 1999-01-07
CA2095300C (en) 2002-06-25
WO1993010234A1 (en) 1993-05-27
EP0625195A1 (en) 1994-11-23
DK0625195T3 (da) 1999-08-30
CA2095300A1 (en) 1994-10-31
GR3029362T3 (en) 1999-05-28
DE69228127D1 (de) 1999-02-18
ATE175442T1 (de) 1999-01-15
DE69228127T2 (de) 1999-09-02

Similar Documents

Publication Publication Date Title
ES2126606T3 (es) Terapia del sistema nervioso central mediante celulas modificadas geneticamente.
DE68929077T2 (de) Transplantieren von genetisch modifizierten zellen zur behandlung von krankheiten des zentralen nervensystems
DK0918848T3 (da) Fremgangsmåder til at behandle kræftsygdomme og patogene infektioner ved anvendelse af antigenpræsenterende celler påfyldt med RNA
NO844579L (no) Enzymresistente immunomodulerende peptider.
DK193788A (da) Fremgangsmaade til isolering af nucleinsyrer
GB8308236D0 (en) Dna vectors
NO874393L (no) Fremgangsmaate for nedsetting av paaler i grunnen, samt apparat for utfoerelse av fremgangsmaaten.
ATE142266T1 (de) Verfahren zum transport von molekülen in eukaryotenzellen
SE8000435L (sv) N-bensylimidazoler med selektivt inhiberande verkan pa tromboxansyntetasenzymet jemte farmaceutiska beredningar innehallande sadana n-bensylimidazoler och sett for deras framstellning
CA2346644A1 (en) Method for preventing xenograft transplant rejection using photodynamic therapy
EP0653491A4 (en) METHOD FOR INTRODUCING FOREIGN DNA IN CELLS.
ES2133714T3 (es) Compuestos heterociclicos para el tratamiento de trastornos del snc y cardiovasculares.
BR8100869A (pt) Processo para o isolamento de substancia solida de caldo de cultura de salinomicina e substancia solida de caldo de cultura de salinomicina
DK0768886T3 (da) Endothelforingseffekter og behandling af vasospastiske lidelser
NO20002412D0 (no) FremgangsmÕte for behandling av tumorer og tumorceller ved anvendelse av ex vivo aktiverte T celler
NO864020L (no) Promoter-anordning for streptomycetes-vektorer.
Jamieson An application of Morita techniques in a university counseling center setting.
JPS6464672A (en) Impact medical treatment device
DK232090D0 (da) Fremgangsmaade og apparat til aftastning af straalingskildefordelingen i et medium, f.eks. proteinfordelingen i en gel
SU1022361A1 (ru) Способ получения капсульного антигена
SU1596731A1 (ru) Способ выделения гормона роста человека
IT8119917A0 (it) Metodo per il trattamento di disturbi del sistema pilifero in mammiferi.
RU97107873A (ru) Способ повышения иммунных свойств переливаемой аутокрови

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 625195

Country of ref document: ES